Abstracts

Activation and Senescence Markers in HCV-Infected Patients on PegIFN/RBV/Telaprevir Tritherapy

Background: Immune activation and senescence described in chronic viral infections is associated with an increase in morbidity and mortality. No data were reported in HCV-infected patients (pts). We describe the immunological markers of activation, senescence and exhaustion in pts initiating PegIFN/RBV/Telaprevir tritherapy. Methodology: Pts with a prior PegIFN/RBV failure who initiated tritherapy (D0) and obtained…

The Effect of Hepatitis C (HCV) Clearance on Macrophage Activation in HIV/HCV Coinfection

Background: Macrophage activation may contribute to accelerated atherosclerosis in HIV-infected persons. We hypothesized that HCV coinfection increases macrophage activation and cardiovascular disease (CVD) risk, and that successful HCV treatment in coinfected persons reduces CVD risk through reduction in macrophage activation. Methodology: Of 54 coinfected subjects who received up to 72 weeks of pegylated interferon/ribavirin (PEG/RBV),…

Association of HIV and HCV Coinfection With Cardiovascular Disease Outcomes Among US Veterans

Background: Human Immunodeficiency Virus and Hepatitis C (HIV/HCV) co-infection is associated with increased risk of acute myocardial infarction (AMI). However, associations with other cardiovascular disease (CVD) outcomes have not been adequately characterized. We aimed to determine the association of HIV/HCV co-infection with various CVD outcomes. Methodology: We conducted a retrospective cohort study using the databases…

HCV Accelerates Non-Liver Mortality in HIV-infected Patients: a Nationwide Cohort Study

Background: HIV worsens the course of HCV infection. Whether HCV infection accelerates HIV progression and non-liver mortality is controversial. HBV treatment guidelines recommend that it be administered to all HIV/HBV patients regardless of liver fibrosis. HCV treatment guidelines recommend that it be administered to HIV/HCV patients with significant (≥F2) liver fibrosis. The aim of this…

Incidence Rates and Risk Factors for Severe Bacterial Infections in HIV/HCV-Coinfected Patients

Background: HIV/HCV co-infection is placing an increasing burden on the health care system. Due to comorbidities and more rapid progression of liver disease associated with co-infection, infectious complications may contribute to excess morbidity. We measured the incidence and identified predictors of severe bacterial infections requiring health service use or leading to death among HIV/HCV co-infected…